Stryker to announce financial results for its second quarter of fiscal year 2025
Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich.
Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)
Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.
Stryker declares an $0.84 per share quarterly dividend
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better.
Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript
Stryker Corporation (NYSE:SYK ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Preston Wells - Vice President, Chief Financial Officer Conference Call Participants Marcus Robert - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Philip Chickering - Deutsche Bank Matthew Miksic - Barclays Patrick Wood - Morgan Stanley Shagun Singh - RBC Mike Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Danielle Antalffy - UBS Matt Taylor - Jefferies Operator Welcome to the First Quarter 2025 Stryker Earnings Call. My name is Luke and I'll be your operator for today's call.
Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.73 per share. This compares to earnings of $2.50 per share a year ago.
Stryker reports first quarter 2025 operating results
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating income margin of 14.3% Adjusted operating income margin (1) increased 100 bps to 22.9% Reported EPS decreased 17.6% to $1.69 Adjusted EPS (1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Organic MedSurg and Neurotechnology 13.4 % (0.8) % 14.2 % 3.5 % 10.7 % Orthopaedics 9.7 (1.0) 10.7 1.4 9.3 Total 11.9 % (0.9) % 12.8 % 2.7 % 10.1 % “Our 2024 momentum continued into the first quarter as we delivered double-digit organic sales growth and continued to expand adjusted operating margins,” said Kevin A. Lobo, Chair and CEO.
